EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials

Behnam Sadeghirad, Yasir Rehman, Azin Khosravirad, Ahmad Sofi-Mahmudi, Sara Zandieh, Jane Jomy, Mansi Patel, Rachel J Couban, Feryal Momenilandi, Robert Burnham, Rudolf W Poolman, Jason W Busse

Osteoarthritis and Cartilage · 2024-10 · 32 (10) · 1207-1219

DOI: 10.1016/j.joca.2024.04.021 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Osteoarthritis and Cartilage, 2024-10. Verfasst von Behnam Sadeghirad und 11 weiteren Autor:innen. Beteiligte Einrichtung: Michael G. DeGroote National Pain Centre, McMaster University, Hamilton, Ontario, Canada; Department of Anesthesia, McMaster University, Hamilton, On…. Hauptthemen laut MEDLINE: Arthralgia, Chronic Pain, Mesenchymal Stem Cell Transplantation, Osteoarthritis, Knee. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To assess the effectiveness of mesenchymal stem cells (MSCs) for chronic knee pain secondary to osteoarthritis (OA). METHODS: We searched MEDLINE, EMBASE, CINAHL, and Cochrane Central to September 2023 for trials that (1) enrolled patients with chronic pain associated with knee OA, and (2) randomized them to MSC therapy vs. placebo or usual care. We performed random-effects meta-analysis and used Grading of Recommendations, Assessment, Development, and Evaluation to assess the certainty of evidence. RESULTS: We included 16 trials (807 participants). At 3-6 months, MSC therapy probably results in little to no difference in pain relief (weighted mean difference [WMD] -0.74 cm on a 10 cm visual analog scale [VAS], 95% confidence interval [95%CI] -1.16 to -0.33; minimally important difference [MID] 1.5 cm) or physical functioning (WMD 2.23 points on 100-point 36-item Short Form Survey (SF-36) physical functioning subscale, 95%CI -0.97 to 5.43; MID 10-points; both moderate certainty). At 12 months, injection of MSCs probably results in little to no difference in pain (WMD -0.73 cm on a 10 cm VAS, 95%CI -1.69 to 0.24; moderate certainty) and may improve physical functioning (WMD 19.36 points on 100-point SF-36 PF subscale, 95%CI -0.19 to 38.9; low certainty). MSC therapy may increase risk of any adverse events (risk ratio [RR] 2.67, 95%CI 1.19 to 5.99; low certainty) and pain and swelling of the knee joint (RR 1.58, 95%CI 1.04 to 2.38; low certainty). CONCLUSIONS: Intra-articular injection of MSCs for chronic knee pain associated with OA probably provides little to no improvement in pain or physical function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArthralgiaChronic PainMesenchymal Stem Cell TransplantationOsteoarthritis, KneeHumansPain MeasurementRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Chronic painKnee osteoarthritisMesenchymal stem cellPhysical function

Autor:innen und Institutionen

  • Michael G. DeGroote National Pain Centre, McMaster University, Hamilton, Ontario, Canada; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Im…
  • Michael G. DeGroote National Pain Centre, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Michael G. DeGroote National Pain Centre, McMaster University, Hamilton, Ontario, Canada; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
  • Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Velenjak, Tehran, Iran.
  • Division of Physical Medicine and Rehabilitation, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Sadeghirad, B., Rehman, Y., Khosravirad, A., Sofi-Mahmudi, A., Zandieh, S., Jomy, J., Patel, M., Couban, R. J., Momenilandi, F., Burnham, R., Poolman, R. W., & Busse, J. W. (2024). Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. Osteoarthritis and Cartilage, 32(10), 1207-1219. https://doi.org/10.1016/j.joca.2024.04.021

Vancouver

Sadeghirad B, Rehman Y, Khosravirad A, Sofi-Mahmudi A, Zandieh S, Jomy J, et al. Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. Osteoarthritis and Cartilage. 2024;32(10):1207-1219. doi:10.1016/j.joca.2024.04.021

BibTeX
@article{Sadeghirad2024,
  author = {Sadeghirad, Behnam and Rehman, Yasir and Khosravirad, Azin and Sofi-Mahmudi, Ahmad and Zandieh, Sara and Jomy, Jane and Patel, Mansi and Couban, Rachel J and Momenilandi, Feryal and Burnham, Robert and Poolman, Rudolf W and Busse, Jason W},
  title = {Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials},
  journal = {Osteoarthritis and Cartilage},
  year = {2024},
  volume = {32},
  number = {10},
  pages = {1207--1219},
  doi = {10.1016/j.joca.2024.04.021}
}
Kostenlos starten →